These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30937843)

  • 1. Transendothelial migration (TEM) of in vitro generated dendritic cell vaccine in cancer immunotherapy.
    Ashraf MU; Jeong Y; Roh SE; Bae YS
    Arch Pharm Res; 2019 Jul; 42(7):582-590. PubMed ID: 30937843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Junctional adhesion molecules mediate transendothelial migration of dendritic cell vaccine in cancer immunotherapy.
    Roh SE; Jeong Y; Kang MH; Bae YS
    Cancer Lett; 2018 Oct; 434():196-205. PubMed ID: 30055289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling.
    Dastmalchi F; Karachi A; Yang C; Azari H; Sayour EJ; Dechkovskaia A; Vlasak AL; Saia ME; Lovaton RE; Mitchell DA; Rahman M
    J Immunother Cancer; 2019 Nov; 7(1):321. PubMed ID: 31753028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells and cancer immunotherapy.
    Radford KJ; Tullett KM; Lahoud MH
    Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmacytoid Dendritic Cells and Cancer Immunotherapy.
    Fu C; Zhou L; Mi QS; Jiang A
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell gene therapy.
    Onaitis M; Kalady MF; Pruitt S; Tyler DS
    Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing dendritic cell-based approaches for cancer immunotherapy.
    Datta J; Terhune JH; Lowenfeld L; Cintolo JA; Xu S; Roses RE; Czerniecki BJ
    Yale J Biol Med; 2014 Dec; 87(4):491-518. PubMed ID: 25506283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
    Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I
    PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximizing dendritic cell migration in cancer immunotherapy.
    Verdijk P; Aarntzen EH; Punt CJ; de Vries IJ; Figdor CG
    Expert Opin Biol Ther; 2008 Jul; 8(7):865-74. PubMed ID: 18549318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
    Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
    Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.
    Homma S; Sagawa Y; Ito M; Ohno T; Toda G
    Clin Exp Immunol; 2006 Apr; 144(1):41-7. PubMed ID: 16542363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell vaccine and cancer treatment: new patents.
    Aleixo AA; Michelin MA; Murta EF
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):26-9. PubMed ID: 24397783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized dendritic cell-based tumor immunotherapy.
    Janikashvili N; Larmonier N; Katsanis E
    Immunotherapy; 2010 Jan; 2(1):57-68. PubMed ID: 20161666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell fusion: from hybridoma to dendritic cell-based vaccine.
    Gong J; Koido S; Calderwood SK
    Expert Rev Vaccines; 2008 Sep; 7(7):1055-68. PubMed ID: 18767954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
    Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
    ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.
    den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Frielink C; Toonen LW; Boerman OC; Figdor CG; Ruers TJ; Adema GJ
    Br J Cancer; 2006 Oct; 95(7):896-905. PubMed ID: 16953240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.
    Garg AD; Coulie PG; Van den Eynde BJ; Agostinis P
    Trends Immunol; 2017 Aug; 38(8):577-593. PubMed ID: 28610825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic Cell-Based Cancer Vaccines.
    Santos PM; Butterfield LH
    J Immunol; 2018 Jan; 200(2):443-449. PubMed ID: 29311386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
    Versteven M; Van den Bergh JMJ; Marcq E; Smits ELJ; Van Tendeloo VFI; Hobo W; Lion E
    Front Immunol; 2018; 9():394. PubMed ID: 29599770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.